The abstract is read at the publisher; the summary is JClub's.
In a prospectively profiled cohort of 1,254 biliary tract cancer patients, 32.2% had level 1/2 actionable alterations, and targeted therapy improved progression-free survival but not overall survival.
- Why it matters: Targeted options exist across biliary tract cancer subsets, yet prior trials have not shown survival benefit, and resistance mechanisms remain insufficiently defined.
- What they did: Using an FDA-authorized targeted NGS assay, investigators mapped OncoKB alterations across anatomic sites, compared targeted therapy versus cytotoxics, and analyzed longitudinal samples for resistance-linked genomic changes.
- The result: Co-occurring TP53/RAS pathway and SMAD4 alterations predicted worse outcomes in IDH1/FGFR2- and ERBB2-driven tumors, respectively, while acquired resistance involved RAS, MEK, MET, MYC, and CDKN2A alterations.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.